Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKT3447 in advanced/metastatic solid tumors
NCT06264921Phase 1Terminated
- Sponsor
- NiKang Therapeutics
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nkt3447 in ovarian cancer, endometrial cancer (EC), gastric cancer (GC) and 4 more (2 arms), sponsored by NiKang Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days and Objective Response Rate at 1 year. Started Feb 2024; status: terminated.
02
Drugs
nkt3447
03
Conditions
ovarian cancerendometrial cancer (EC)gastric cancer (GC)gastroesophageal junction cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06264921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264921.